Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target

Market Focus

06/24

On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.

On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.

Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1148915961"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148915961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148915961?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148915961","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target","media":"Market Focus","content":"<p><p>On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.</p><p>On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.</p><p>Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.</p><p>On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.</p><p>Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1148915961","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148915961","pubTimestamp":1782288462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"走势提示|Argenx SE盘前涨3.55%法巴启动跑赢大盘评级目标1219美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}